Aranesp® (darbepoetin alfa) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	Email:	

Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured: _____

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured: _____

Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:	Last Name: *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.				
Address:	City:	State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:	Office Contact Name:	Phone:			

Specialty *(Check one):* ☐ **Oncologist** ☐ Nephrologist ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other: _____
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for Aranesp (darbepoetin alfa) Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For ALL Requests (Clinical documentation required for all requests):
☐ Yes ☐ No Will the requested drug be used concomitantly with other erythropoiesis stimulating agents (ESAs)?
☐ Yes ☐ No Has the patient received erythropoiesis stimulating agent (ESA) therapy in the previous month (within 30 days of request)?

For Initiation Requests (Clinical documentation required for all requests):
☐ Yes ☐ No Has the patient been assessed for iron deficiency anemia?
Please indicate the patient's most recent serum transferrin saturation (TSAT) level and date of test: ____% Date of test: ____/____/____
☐ Yes ☐ No Is the patient receiving iron therapy?
☐ **Anemia in chronic kidney disease (CKD)**
Please indicate the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion): _____ Date of test: ____/____/____

Continued on next page

Aranesp® (darbepoetin alfa) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ **Anemia due to myelosuppressive chemotherapy**
☐ Yes ☐ No Does the patient have a non-myeloid malignancy?
Please indicate the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion): _____ Date of test: ____/____/____

☐ **Anemia in myelodysplastic syndrome (MDS)**
Please indicate the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion): _____ Date of test: ____/____/____
Please indicate the patient's pretreatment serum erythropoietin (EPO) level: _____

☐ **Anemia in patients whose religious beliefs forbid blood transfusions**
Please indicate the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion): _____ Date of test: ____/____/____

☐ **Anemia in primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis**
Please indicate the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion): _____ Date of test: ____/____/____
Please indicate the patient's pretreatment serum erythropoietin (EPO) level: _____

☐ **Anemia due to cancer**
☐ Yes ☐ No Is the patient undergoing palliative treatment?

For Continuation Requests (clinical documentation required for all requests):
☐ Yes ☐ No Has the patient completed at least 12 weeks of erythropoiesis stimulating agent (ESA) therapy?
→ Please indicate the number of weeks completed: _____
→ ☐ Yes ☐ No Has the patient been assessed for iron deficiency anemia
Please indicate the patient's most recent serum transferrin saturation (TSAT) level and date of test: _____% Date of test: ____/____/____
☐ Yes ☐ No Is the patient receiving iron therapy?
☐ Yes ☐ No At any time since the patient started ESA therapy, has the patient's Hgb increased by 1 g/dL or more?
Please indicate the patient's current hemoglobin (Hgb) level (exclude values due to a recent transfusion) and date of test: _____
Date of test: ____/____/____

Anemia due to myelosuppressive chemotherapy only:
☐ Yes ☐ No Does the patient have a non-myeloid malignancy?

Anemia due to cancer only:
☐ Yes ☐ No Is the patient undergoing palliative treatment?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required):* _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.